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Abstract. The emergence of transplantation has seen the development of 
increasingly potent immunosuppressive agents, progressively better 
methods of tissue and organ preservation. refinements in histocompati-
bility matching. and numerous innovations in surgical techniques. Such 
efforts in combination ultimately made it possible to successfully engraft 
all of the organs and bone marrow cells in humans. At a more fundamen· 
tal level, however, the transplantation enterprise hinged on two seminal 
turning points. The first was the recognition by Billingham. Brent, and 
Medawar in 1953 that it was possible to induce chimerism·associated 
neonatal tolerance deliberately. This discovery escalated over the next 15 
years to the first successful bone marrow transplantations in humans in 
1968. The second turning point was the demonstration during the early 
1960s that canine and human organ allografts could self·induce tolerance 
with the aid of immunosuppression. By the end of 1962. however. it had 
been incorrectly concluded that turning points one and two involved 
different immune mechanisms. The error was not corrected until well into 
the 1990s. In this historical account. the vast literature that sprang up 
during the intervening 30 years has been summarized. Although admira· 
bly documenting empiric progress in clinical transplantation. its failure 
to explain organ allograft acceptance predestined organ recipients to 
lifetime immunosuppression and precluded fundamental changes in the 
treatment policies. After it was discovered in 1992 that long.surviving 
organ tnmsplant recipients had persistent microchimerism. it was pos· 
sible to see the mechanistic commonality of organ and bone marrow 
transplantation. A clarifying central principle of immunolollY could then 
be synthesized with which to guide efforts to induce tolerance systemati· 
cally to human tissues and perhaps ultimately to xenografts. 
How transplantation came to be a clinical discipline can be pieced 
togethcr by perusing two volumes of reminiscences collected by 
Paul I. Tcrasaki during 1991-1992 from many of the persons who 
were directly involved. One volume was devoted to the discovery 
of the major histocompatibility complex (MHC). with particular 
reference to the human leukocyte antigens (HLA) that arc widely 
used today for tissue matching [I]. The other focused on mile-
stones in the dcvt!lopment of clinical transplantation [2]. All of the 
contrihutions descrihed in hoth volumes can he traced hack in one 
way or other to the demonstration more than a half century ago by 
Peter Brian Medawur that the rejection of allografts is an immu-
nologic phenomenon ]3 . .f]. 
Ten years later (1953) Billingham. Brent. and Medawar [5] 
showed that tlllemnce to skin allografts Clluld he induced hy 
inoculating Ictal or prenatal mice with immunocompetent spleen 
cells from adult donors. Because of their immunologic immatu· 
rity. the recipients were ineapahle of rejecting the spleen cells 
whose progeny survived indctinitely. Specitic nonresponsiyeness 
to donor strain tissues was retained as the recipient animals grew 
to adult life, whereas normal reactivity evolved to third party 
grafts and other kinds of antigens. 
This was not the first demonstration that tolerance could be 
deliberately produced. Analogous to the neonatal transplant 
model. Traub [6] showed in 1936 that the lymphocytic choriomen-
igitis virus (LCMV) persisted after transplacental infection of the 
embryo from the mother or. alternatively. by injection into new-
born mice. Howevt!r, when the mice were infected as adults. the 
virus was eliminated immunologicully. Similar observations had 
been made in experimental tumor models. Murphy [7] reported in 
1912 the outgrowth of Rous chicken sarcoma cells on the cho-
rioallantoic membranes of duck or pigeon egg embryos. which 
could he reversed by inoculation of adult chicken lymphoid cells 
[8], whereas sarcoma implantation into adults was not possible. 
The observations of Murphy and Traub did not influence the 
t!arly development of transplantation. Instead. the impetus and 
rationale for the experiments of Billingham et al. [5,9] and similar 
ones in chickens hy Hasek [10] originated with Owen [II]. who 
demonstrated that freemartin cattle [the calf equivalent of human 
fraternal (dizygotic) twins] hecame permanent hematopoietic chi-
meras if fusion of their placentas existed in utero. allowing fetal 
cross-circulation (Fig. I): such animals permanently accept each 
other's skin [12]. Burnet and Fenner [14] predicted that this 
natural chimerism and tolerance to other donor tissues and organs 
could be induced by the kind of experiments successfully per-
formed hy Billingham et al. Howt!ver. Billingham and Brent [15. 
16] soon learned in mice_ parallel with similar observations by 
Simonsen [17] in chickens. that tile penalty for infusing immuno-
wmpetent hematopoietic cells was graft-versus· host disease 
(GVHD) unless there was a close genetic relationship (i.e .. his-
tocompatihility) between the donor and recipient. 
This was the beginning of modern transplantation immunology. 
an extensive history of which has heen written hy Brent [I X]. one 
of its principal architects. Each cell- and organ-defined branch of 
transplantation also has had its historians. who huYe described the 
stages through which specific procedures moved to the bedside 
from experimental lahoratories-or in some cases directly. The 
culminating clinical events can be capsulized with a list of the tirst 
,>uccessful allotransplantation in humans of the kidney [19]. liver 
120]. heart [21. 2:!\.lung 123]. pancreas (24]. intestine [25]. multi-
ple abdominal viscera [26]. and bone marrow [27-30]. 
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Fig. 1. Chimerism in freemartin (fraternal twins) described by Owen [I t 1. 
Cross-tolerance to formed blood elements followed intrauterine circula-
tal)' exchange in dizygotic twins. Mutual tolerance to skin grafts was later 
proved by Anderson et al. with Medawar [121. (From Starzl and Butz [13J. 
with permission.) 
Although such milestones and dozens of lesser ones arc impor-
tant. the emphasis in this account is on developments that were 
applicable to all varieties of allografts and responsible for major 
transitions in transplantation ideology. It becomes apparent as the 
layers of history arc peeled away that §:ere were only two seminal 
turning points in the evolution of clinical transplantation. One was 
the induction of chimerism-associated nconatal tolerance by Bill-
ingham. Brcnt. and Medawar in 1<)53. The sccond was the dcm-
onstration during 1%2-1%3 that organ allografts could self-in-
duce tolerance ~ith the aid of im~unosuppressiongiill All 
subsequent developments in organ transplantation depended on 
cxploitation of this principle. using variations of the drug strategy 
that had made its discovery possible. Ironically. the down side of 
the resulting revolution in organ transplantation was the early 
introduction of a conceptual error that distorted the maturation of 
transplantation immunology and adversely affected the orderly 
development of gcneral immunology. 
The error. which was not corrected until well into the 1990s 
[32-3-i1. was thc conclusion by consensus that organ allograft 
acceptance IIlvolvcd mechanisms different from the chimerism-
dependent ones of neonatal tolerance and its clinical analogue 
hone marrow transplantation. Consequently. the vast literature 
that sprang up during the intervening 30 years admirably docu-
mented the progression of improvements in clinical transPI'\2t:Jj 
tion while failing to explain what was being accomplished 351. 
Therefore the reader may protit by skipping III the last section of 
this article (Allograft Acceptance versus Acquired Tolerance) 
hefore attempting to understand what went on hetween 1963 and 
Il)ll3 and hefore. 
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Table l. Direction of acceptable organ transfer when the donor and 
recipient have different ABO red blood cell types. 
Transfer" 
o to non-O 
Rh- to Rh+ 
Rh+ to Rh-
A to non-A 
B to non-B 
AB to non-AB 
From Starzl [541. 
Acceptability 
Safe 
Safe 
Relatively safe 
Dangerous 
Dangerous 
Dangerous 
"For organ transplantation. 0 is the universal donor and AB is the 
universal recipient. With the transplantation of bone marrow allografts or 
lymphoid-rich organ allografts (e.g., intestine or liver). enough anti-host 
isoagglutinins may be produced by the allograft to cause serious or lethal 
hemolvsis in a significant number of cases (humoral graft-versus-host 
disease [55]). Consequently. the rules summarized in this table are fully 
applicable only with leukocyte-poor organs such as the kidney and heart 
(see section on Allograft Acceptance versus Acquired Tolerance). 
Prehistory: Before Immunosuppression 
An indelible mark on the pages of transplantation history was left 
with the perfection of techniques for organ revascularization using 
surgical anastomosis by Alexis Carrel at the beginning of the 
twentieth century [36]. Aside from the technical contributions. 
which provided the foundation for conventional vascular surgery. 
Carrel recognized that transplanted organ allografts were not 
permanently accepted. although he did not know why. 
Using vascular surgical techniques. animal research on trans-
plantation was most highly focused on the kidney for most of the 
next half century [37-39]. The extrarenal vacuum rapidly was filled 
between 1958 and L 960 with the development in several labora-
tories of canine models with which to study all of the intraabdomi-
nal organs [40-44] and thoracic organs [45-47]. Although each 
organ presented specific technical and physiologic issues. the core 
problems of immunosuppression. tissue matching. and allograft 
preservation eventually were worked out mainly with the kidney 
and liver and applied to other organs with minor modifications. 
Hetero (Xcno) Transplantation 
The tirst known attempts at clinical renal transplantation by vas-
cular anastomoses were made hetween the beginning of the twen-
tieth century and 1923 in France [4X]. Germany [4<)]. and else-
where (summarized in [50]) using pig. sheep. goat. and subhuman 
primate donors. None of the kidneys functioned for long. if at all; 
and the human recipients died a few hours to 9 days later. No 
further animal-to-human transplantations were tried again until 
1963. after immunosuppression was available 151. 521. 
Homo EI~"EFF Trallsplallll/fioll 
III 11)36 Voronoy of Kiev. Russia. reported the transplantation of 
a kidney from a cadaver donor of B ,. hlood type to a recipient of 
0+ blood type [531. in violation of what han: hecome accepted 
rules of tissue transfer [5-i. 55] (Table I). III addition. the allograft 
was jeopardized by the residual risk of aeut!.! mercury poisoning 
(from a suicide attempt). which had caus!.!d the recipient's renal 
failure. A tinal advers!.! factor was (ile 6-hour laps!.! b!.!tween the 
donor's death and organ procurcment. Th!.! allograft did not 
produc!.! any urine during the -is hours of tht: palit:nt's posttrans-
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plant survival. Although other attempts may have been made by 
Voronoy [56], another 15 years passed before significant kidney 
transplant activities were resumed in France. 
In 1952 Rene Kuss [57J and Charles Dubost [58] in Paris and 
Marceau Serve lie [59J in Creteil carried out a series of renal 
transplantations with kidneys removed from convict donors im-
mediately after their execution by guillotine. The next year. the 
French nephrologist Jean Hamburger. in collaboration with urol-
ogist Louis Michon at the Hopital Necker in Paris. rcported a 
mother-to-son transplantation of a kidney that functioned well for 
3 weeks before being rejected [60). The procedure developed by 
Kuss and the other French surgeons and used for this first live 
donor kidney transplantation has been performed hundreds of 
thousands of times since then. The operation's relative freedom 
from chronic morbidity would soon be dcmonstrated with the 
identical (monozygotic) twin transplantations of Joseph E. Mur-
ray and John Merrill and their associates [61 J at the Peter Bent 
Brigham Hospital in Boston. 
The etIorts by the French teams were widely known. and visitors 
flocked to Paris during the early 1950s to learn first-hand from the 
experience. One of the observers of the extraperitoneal pelvic 
operation (often called the Kuss procedure in Europe) was John 
Merrill. as Hume and Merrill et al. (62) described in their account 
of the first clinical trials at the Peter Bent Brigham Hospital. 
Among Hume's nine Boston cases. howt!ver. all but one of the 
allografts were placed in the recipient thigh. revascularized from 
the femoral vessels, and provided with urinary drainage by skin 
ureterostomies. 
The exceptional case in the Boston series [62J was the first one. 
The donor and recipient opt!rations were performed in Spring-
field. Massachusetts. on March 30. 1l)51. by L.H. Doolittle. The 
donor kidney. excised because of a carcinoma of the lower ureter, 
was implanted in the vacated renal fossa of the recipient after 
removing the native organ. The recipient patient had been under 
short-term dialysis care at the Brigham. where the first artificial 
kidney in the United States had been brought from Holland by 
Wilhelm Kolff and modified by Harvard engineers. as described in 
detail by Moore [63J. 
The next eight operations. in which the allografts were placed in 
the anterior thigh. were performed by Hume in Boston between 
April 23. 1951. and December 3. I \}52. The rcport of the nine 
cases stands as one of the medical classics of the twentieth cen-
tury. providing an extensive clinical and pathologic profile of renal 
allograft rejection in untreated human recipients. The descrip-
tions compI.:mented the report of Michon and Hamburger of the 
live-donor French case (set! earlier [hO!) and pathfinding studies 
in dogs hy Morten Simonsen in Denmark PHI and of W. James 
Dempster in England [J\}J. It is noteworthy that Hume treated 
some of his patients with adrenal cortical steroids. It was alreadv 
known from experimental studies that stcroid therapy modestly 
mitigated primary skin graft rcjection [h-!-h61 and even slowed 
the accelerated rejection of presensitized recipients Ih7J. 
Although Cllmpilation of the Boston scries postdatcd the early 
French elIorts (as generously annotated hv Humc I. the commit-
ment of the Harvard group to transplantation was eVident long 
before the availahility of ellcctivc immunosuppression. Hume. 
who moved in 1956 from Boston tll the Medical Colt.:gc of 
Virginia (Richmond). remained a major force in transplantation 
until his dcath in the crash lIf a private plane (of which he was thc 
pilot) ncar LllS Angelcs in Mav 1'17.'. illS friend and colleague. 
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John Merrill. who remained in Boston. drowned off the beach of 
a Caribbean island in 1984. 
None of the European and American efforts to this time. or all 
togt!ther. would have had any lasting impact on medical practice 
were it not for what lay ahead. The principal ingredients of organ 
transplantation-immunosuppression. tissue matching, organ 
procurement (and preservation)-were still unknown or undevel-
oped. The only unequivocal example of clinically significant allo-
graft function through 1954 was provided by one of the nonim-
munosuppressed patients of Hume et al. [62) whose thigh kidney 
produced life-supporting urine output for 5 months. Similar 
claims about function of an allograft transplanted to the ortho-
topic location [68] (i.e., as in Doolittlc's case (62)) or to a non-
anatomic site [69] were considered implausible by later critics. 
The existence of these cases was public knowledge. but the 
failure of all the grafts (usually with death of the patient) left little 
room for optimism. The perception. if not thc reality. of hopc-
lessness was changed at the Petcr Bent Brigham Hospital 2 days 
before Christmas 1954 when a kidnt!y was removed from a healthy 
man by urologist J. Hartwell Harrison and transplanted by Joseph 
E, Murray 10 the pelvic location of the donor's uremic. identical 
twin brother [61. 70]. Although no effort was made to preserve the 
isograft. it functioned promptly despite 1-l2 minutes of warm isch-
emia. The recipient lived for nearly 25 years before dying of 
atherosclerotic coronary artt!ry disease. 
According to Merrill et al. [61]. exploitation of genetic identity 
for wholt! organ transplantation had bcen suggested by the recip-
ient's physician. David C. Miller. of the Public Health Service 
Hospital. Boston. It already was well known that identical twins 
did not reject each others' skin grafts [71). To ensure identity. 
reciprocal skin grafting was performed in the Boston twins. Al-
though the identical twin cases attracted worldwide attention. 
organ transplantation now had reached a dead end. Further 
progress in the presence of an immunologic barrier would require 
clfectivc immunosuppression. The possibility of meeting this ob-
jective could only be regarded as bleak. To understand why, it is 
necessary to appreciate not only how harren the landscape of 
immunology was but also how slowly the prcexisting information 
had been filled in. 
A century had passed between the tirst vaccination procedure in 
17\}6 (Edward Jenner. small pox) and confirmation of the immu-
nization principle by Louis P4Isteur (with chicken cholera and 
rabies). The proof obtained by Robert Koch that microorganisms 
caused anthrax (11i76) and subsequently many other infectious 
diseases stimulated a search for the host's protective mechanisms. 
This search yielded components of the immune response: anti-
hodies [Emil Adolf Von Behring and Shibasaburo Kitasato 
(11i\}O)I. immune cells [llya Metchnikolf (11i1i4)1. and complement 
[Jules Bordet (ISl):'i)j. In addition. Paul Erlieh developed the side 
chain theory (I:-il)()). according to which each cell has a vital celller 
of protein substance and a series of side chains (later known as 
receptors 1 to which toxic suhstanccs and nutrients were absorbed 
and then assimilatcd. In 1910 Erlich introduced the tirst antimi-
LTooial drug. <In arsenical compound ctkctive against syphilis. 
~awsK <lnd se"eralother infections. 
Decadcs passed hetween the clustcr ot great contrihutions at 
the turn of the t\\entieth ccntury and the proposal by F. McFar· 
iane Burnet that antibodies wcrc produced in each individual only 
III those antigens to which he or she was exposed [14J. The lack of 
major movement between events IS eVident from <I lisl ot Nobel 
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Table 2. Nobel Prizes related to immunology/transplantation. 
Year Name 
1901 Emil Adolf Von Behring 
1905 Heinrich Hermann Robert Koch 
1908 Paul Ehrlich 
I1ya Metchnikoff 
1912 Alexis Carrel 
1919 Jules Bordet 
1930 Karl Landsteiner 
1960 Sir Frank MacFarlane Burnet 
Sir Peter Brian Medawar 
1972 Gerald M. Edelman 
Rodney R. Porter 
1980 Baruj Benacerrat 
Jean Dausset 
George Davis Snell 
1984 Niels Kaj Jerne 
Georges I.F. Kohler 
Cesar Milstein 
1985 Michael Stuart Brown and 
Joseph Leonard Goldstein 
1987 Susumu Tonegawa 
1988 Gertrude Belle Elion and 
George Herbert Hitchings 
1990 Joseph E. Murray 
E. Donnall Thomas 
1996 Rolf Zinkernagel and Peter C. Doherty 
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Accomplishment 
Discoverv of antibodies 
Cause ,!I;d <.:trect of microorganisms and infection 
Side chain (receptor) concept: champion of humoral immunity: 
antimicrobial therapy 
Champion of cellular immunity 
Vascular surgery and transplantation 
Discoverv of complement 
aiscover~d ABO blood group antigens 
Clonal selection hypothesis 
Acquired transplantation tolerance 
Characterized immunoglobulins 
Clarified structure of a'iitibodv molecule 
Discovered immune response" genes and collaborated in discovery 
of major histocompatibility complex (MHC) restriction 
Discovered first HLA antigen 
Discoverv of MHC in mice 
fmporta~t immunologic hypotheses 
Hvbridoma technologv 
Hybridoma technology 
Hepatic control of cholesterol metabolism (with Goldstein)" 
Discovered somatic recombination of immunologic receptor 
genes 
Co-discovery (with Hitchings) of 6-mercaptopurine and 
azathioprine 
Kidney transplantation 
Bone marrow transplantation 
Co-discovered (with Doherty) the role of MHC restriction in 
adaptive immune response to pathogens 
From Schlessinger and Schlessinger [72]. © 1991. with permission of Oryx Press. ~EF41 N. Central Avenue. Suite 700. Phoenix, AZ 85012; 
800-279'0799. 
"Proved with liver transplantation for indication of hypercholesterolemia (73. T~zK 
Prizes [72) (Table 2). Although 6 of the first 17 Nobel laureates 
(1901-1919) were honored for work relevant to immunology/ 
transplantation. there was only one more example (Karl Land-
steiner, ABO blood groups) among the next 57 (\ 920-1 (59). 
Beginning with Burnet and Medawar (see above). 17 of the 77 
laureates since 1960 have been directly responsible for. contrib-
uted to. or directly benefited from, advances in transplantation 
(Table 2). 
In Burnet's original hypothesis of immunity. antibody synthesis 
was postulated to occur after an antigen locked onto a membrane-
bound receptor (a version of the antibody) displayed at the sur-
face of an immune cell. After binding the antibody. the cell 
proliferated. producing a clone that secreted identical antibodies 
(the clonal selection theory). Nossal subsequently proved that the 
clone rose from a single cell ("one cell/one antibody") [75). Al-
though Burnet's hypothesis was not yet complete. it was to be-
come the cornerstone of modern immunology. 
Concept of Immunosuppression 
With Recipiem Cytoablatioll 
The transition of tissue and organ transplantation from an exer-
cise in futility to tenuous practicality involved a surprisingly small 
number of advances. which were interspersed over long periods of 
frustration. After Medawar's demonstration in 1044 that rejection 
was an immunologic event [3. 4). a logical and inevitable question 
was: Why not protect the organ allograft hy weakening the il11-
mune system? This idea was tested in rabbits during 1950-1951 
with cortisone [64. (5) and total body irradiation [76). Both tech-
niques prolonged skin graft survival for only a few days. 
Neither these results. nor those reported with cortisone in 1952 
by Cannon and Longmire [66) in a chicken skin graft model 
generated much optimism. However. the Cannon-Longmire re-
port contained three observations that, in retrospect, presaged not 
only the acquired neonatal tolerance produced by Billingham, 
Brent. and Medawar the following year but also the most impor-
tant clinical advances in transplantation of the succeeding de-
cades. First, skin grafts exchanged between I-day-old chicks of 
ditferent breeds had a high rate of initial engraftment and a 6% 
incidence of permanent take. Second. the window of neonatal 
opportunity was gone by 4 days. Third, and most important. the 
percent of permanent engraftment of neonatally transplanted skin 
\Vas increased to more than 20% by a course of cortisone. with no 
increase of mortality. 
The significance of the third observation was recognized by 
Cannon and Longmire who wrote: ":'\/though the cortisone did 
not entirely prevent a reaction in the homograft, it did decrease 
the incidence of reaction. Even more important. the increased 
incidence of reaction [sicl free grafts appeared to maintain itself 
after the drug was discontinued. This phenomenon is one which 
lip to the present time has not been found in homograft experi-
ments on mammals and humans." 
Despite a confirmatory follow-up study in 1957 [77], the ne-
glected Cannon-Longmire article faded quickly from the collec-
tive memory of both hasic scientists and clinicians. In contrast. the 
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achievement of acquired neonatal tolerance by Billingham et ai. in 
1953 [5, 9] ignited interest in transplantation as never before. Two 
years later, Main and Prehn [78] attempted to simulate in adult 
mice the environment that allowed the acquisition of neonatal 
tolerance. The three steps were (1) to cripple the immune system 
with supralethal total body irradiation (TBI): (2) to replace it with 
allogeneic bone marrow (producing a hematolymphopoietic chi-
mera); and (3) to engraft skin from the same inbred strain as the 
donor of the bone marrow. 
The experiments were successful [79, 80]; but as with the neo-
natal tolerance model, lethal GVHD could be avoided only when 
there were "weak" histocompatibility barriers. Applying the chi-
merism strategy for kidney transplantation in beagle dogs in Coo-
perstown, New York, Mannick et al. [80] reported good renal 
allograft function in a supralethally irradiated recipient, which 
also was given donor bone marrow and was a hematolymphopoi-
etic chimera; the animal lived for 73 days before dying of pneu-
monia. Because it was demonstrated later that this outcome de-
pended on the identity of the dog lymphocyte antigens (DLA) [81. 
82], an accidental DLA match was suspected in retrospect to have 
been present in Mannick's experiment. Efforts by Hume et ai. [83] 
and subsequently by Rapaport et al. [84] and others to broaden 
the range of acceptable histocompatibility inevitably led to lethal 
GVHD, rejection, or both. 
Bone Marrow Transplantation. With the impasse. workers in bone 
marrow and whole organ transplantation took separate pathways. 
Bone marrow transplantation was dependent a priori on the 
classic chimerism-associated acquired tolerance induction defined 
at the outset by Billingham. Brent, and Medawar in the neonatal 
model. Despite the fact that only highly histocompatible donors 
could be used. clinical success with bone marrow engraftment was 
achieved in 1963 by Mathe et ai. in Paris [27], whose patient lived 
for 2 years with chronic GVHD before committing suicide. 
Five years later, Gatti and Good et al. in Minneapolis [29] and 
Bach et al. at the University of Wisconsin (28] each transplanted 
hone marrow to recipients who are well today. The lifetime ell'orts 
of Thomas [30], van Bekkum [85], and others fueled the matura-
tion of hone marrow transplantation into accepted clinical therapy 
for numerous hematologic diseases (including malignancies). ac-
quired immune deficiency disorders. mesenchymally hased inborn 
errors of metabolism. and an assortment of other indications. 
Bone marrow transplantation was an intellectual triumph. Its 
development could be traced in a straight line back to the exper-
iments of Main and Prehn [78] and before that to the acquired 
neonatal tolerance of Billingham. Brent. and Medawar [5. 91 and 
the natural tolerance of Owen's freemartin cattle [II]. 
W'hole Organ Transplalllotion. In contrast. clinical organ trans-
plantation. the wide clinical use of which preceded hone marrow 
transplantation by a decade. appeared to be uisconnected from a 
rational base when it was concluded that organ engraftment seem-
ingly was independent of chimerism. An extension of the Main-
Prehn strategy (i.e .. lethal TBI followed hy bone marrow and 
kidney allografts. as in Mannick's dog) was used by Murray et al. 
[86] in only two cases. both in IlI58. The next 10 kidney recipients 
in Boston were conditioned with slthll't/wl TBI wi/how hOIlC mar-
row [19.86.87). Eleven of the twelve irradiated patients died after 
o to 28 davs. 
The surviVor (who was not given bone marrow) had adcquatc 
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Table 3. Kidney transplantation with 2: 6 months survival as of March 
1963. 
Survival 
Case City" Refs. Date Donor (months)" 
Boston 19.86.87 1/24/59 Fraternal twin > 50 
, Paris 88.89 
-
0129159 Fraternal twin > 45 
3 Paris 90 6/22/60 Unrelated' 18 (died) 
4 Paris 89 12/19/60 Mother 12 (died) 
5 Paris 90 3112161 Unrelated' 18 (died) 
(, Paris 88 2/12/62 Cousin' >13 
7 Boston 87. 111 4/5162 Unrelated 10 
UBoston: J. E. Murray (cases 1, 7); Paris: J. Hamburger (cases 2. 4, 6) 
and R. Kuss (cases 3. 5). 
hThe kidneys in patients I. 2. and 6 functioned for 20.5. 25, and 15 
years. respectively. Patient 7 rejected his graft after 17 months and died 
after return to dialysis. 
'Adjunct steroid therapy. 
renal function from the time his fraternal twin brother's kidney 
was transplanted on January 24. \lI59 until he died in July 1979 
(Table 3). With this historical accomplishment. the genetic barrier 
to organ transplantation had been definitively breached for the 
first time in any species [19]. Five months later Hamburger et al. 
[88] added a second fraternal twin transplantation, using the same 
treatment (Table 3). This second recipient had good renal func-
tion until his death 26 years later from carcinoma of the urinary 
bladder. 
In these two dizygotic twin cases, it was conceivable that the 
donor and recipient placentas had fused during gestation, analo-
gous to Owen's freemartin cattle (see ahove and Figure I). This 
suspicion was put to rest at the Paris centers of Jean Hamburger 
[89] and Rene Kuss (90] by four more examples during 1960-\962 
of survival of more than I year. In Kuss's two cases the donors 
were not related (Table 3). During the critical period from Jan-
uary 1959 through the spring of 1962, the cumulative French 
experience was the principal (and perhaps the only) justification 
to continue clinical trials in kidney transplantation. 
The experience from Boston and Paris summarized in Table 3 
showed that bone marrow infusion was not a necessary condition 
for prolonged survival of kidney allografts and ostensibly elimi-
nated the requirement of chimerism. The stage was set for drug 
therapy. In fact, hath Hamhurger and Kuss mentioned the use of 
adrenal cortical steroids as an adjunct to TBI (Table 3): but 
neither the dose nor thc indication for the steroids was described. 
In addition. Kuss secondarily administered 6-mercaptopurine (6-
MP) to one of his cytoahlated patients as early as August 1%0 
[<)0]. "on the basis of the recent results of the experimental studies 
conducted by Caine" [9 I] (sec also next section), Calm: had made 
an invited visit to the Paris center a few months earlier (R. Kuss 
and R. Caine. personal communication). 
Some authorities have considcreLl irradiation-induceLl and 
drug-induced graft .Icceptance to he dilkrent phenomena 150. X7. 
92]. More recently. it has hecomc obvious that the variable de-
grees of graft acceptance achieved with sublethal TBI hetween 
January 1959 anLl February I %2 were fundamentally the same as 
that seen in tens of thousands of drug-treated humans following 
transplantation of various whole organs (sec Allograft Acceptance 
\crsus Acquired Tolerance). 
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With Drug Immunosuppression 
After it was learned that TBI alone could result in prolongation of 
kidney allografts, it was logical to focus the search for immuno-
suppressive drugs on myelotoxic agents whose effects mimicked 
those of irradiation. In September 1960 Willard Goodwin of Los 
Angeles produced severe bone marrow depression with metho-
trexate and cyclophosphamide in a young female recipient of her 
mother's kidney. The patient subsequently developed multiple 
rejections that were associated with bone marrow recovery. They 
were temporarily reversed with prednisone several times during 
the 143 days of survival. It was the first example of protracted 
human kidney allograft function with drug treatment alone [93]. 
However. the case was not reported until 1963. 
Kidney transplant surgeons were quick to realize that bone 
marrow depression should be avoided. not deliberately imposed. 
following the demonstration by Schwartz and Dameschek [94] 
that 6-MP in a nontransplant rabbit model was immunosuppres-
sive in submyclotoxic doses. Within a few months after their 
seminal discovery. Schwartz and Dameschek [95] and Meeker [96] 
(working with Condie. Weiner. Varco. and Good) showed that 
6-MP caused a dose-related delay of skin graft rejection in rabbits. 
Aware of these results but independent of each other. Caine [97] 
in London and Zukoski. Lee, and Hume [98] in Richmond. Vir-
ginia. demonstrated the same thing in the canine kidney trans-
plant model. In June 1960 CaIne moved from the Royal Free 
Hospital to join Murray at the Peter Bent Brigham Hospital 
(Boston) for further preclinical studies of 6-MP and its analogue 
azathioprine [87. 99-101]. 
The two drugs had heen developed originally by Gatrude Elion 
and George Hitchings as antileukemia agents [102]. Their possihle 
use for transplantation was greeted at first with feverish enthusi-
asm hecause it was generally conceded that recipient cytoablation 
would permit success in only occasional cases of human renal 
transplantation. Although approximately 95c,{ of the mongrel ca-
nine kidney recipients treated with 6-MP or azathioprine died 
within less than 100 days from rejection or infection. occasional 
examples were recorded of long-term or seemingly permanent 
allograft acceptance [103-106] following discontinuance of a 4- to 
12-month course of immunosuppression. The number of these 
animals was discouragingly small, hut it was an accomplishment 
never remotely approached using TBI. with or without adjunct 
hone marrow. Survival of Mannick's single cytoablatcd animal for 
73 days after comhined hone marrow and kidney transplantation 
had been the previous high water mark in dogs (see earlier [HO]). 
The survival of some of CaIne's animals beyond 6 months led to 
the decision at the Brigham to begin clinical trials with chemical 
immunosuppression. However, the poor therapeutic margin of the 
6-MP and azathioprine when used alone in dogs was recognized. 
Caine and Murrav also were forewarned hy an earlier clinical 
experience of Hopewell. CaIne. and Beswick [107]. which was not 
puhlished until I %~K in which 6-MP had been used to treat three 
kiunev recipients (including one with a living donor) during 1959-
1()60: all three recipients had died. 
Consequently. the canine studies of 6-MP and azathioprine in 
Boston were highly focused on finding more dt'cctive drug com-
hinations [1'17. lJlJ. 10 l. 10H]. Although :Idrenal cortical steroids 
were tested. they did not appear to potentiate the value of aza-
thiopnne [Ill). to II. prompting Murrav in hiS clinical trial to opt 
for adjunct cytotoxic agents such as azaserine and actinomycin C 
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[87]. Only one of the first I () kidney recipients treated with either 
6-MP (/I = 2) or azathioprine-based immunosuppression (n = 8) 
survived more than 6 months (the last one in Table 3) [87, 111]. 
At the nadir of the resulting pessimism. two reproducible ob-
servations. first in dogs and then in humans. were made at the 
University of Colorado. Taken together. these findings profoundly 
shaped future developments in transplantation of all organs and 
eventuallv of hone marrow. The observations were encapsulated 
in the titie of a report puhlished in October 1963: "The Reversal 
of Rejection in Human Renal Homografts with the Subsequent 
Development of Homograft Tolerance" [3\). 
The reversal was readily accomplished by temporarily adding 
unprecedented high doses of prednisone (200 mg/day) to baseline 
immunosuppression with azathioprine. The evidence that the liv-
ing donor kidneys had self-induced tolerance under an umbrella 
of immunosuppression was equally clear. Most of the recipients 
had a subsequent progressively diminishing need for immunosup-
pression. usually to doses lower than those that initially failed to 
prevent rejection. Thc tolerance was complete enough to allow 
the patients to go home to an unrestricted environment. Nine of 
the first ten of these kidney recipients achieved prolonged graft 
survival [31]. including two who hear the longest continuously 
functioning allografts in the world today (more than 35.5 years) 
and have been free from immunosuppression for 32 and 4 years. 
respectively [109]. 
The practical and theoretic implications of these observations 
were recognized throughout the report [31]: 
A state uf relative immunologic non-reactivity seems to have been pro-
duced which has lasted for as long as h months .... It is not knuwn whether 
this is due to a change in the antigenic properties of the homograft. or to 
an alteration in the specific [hostl response to the stimulus of the grafted 
tissues. The apparent host-graft adaptation does. however. provide some 
hope for prolonged functional sUlVival. . .. It wuuld seem probable that 
the [thaapeuticj principles. as ddined with the kidney. can eventually be 
applied tu other organ homografts .... The prior knowledge that a rejec-
tion crisis is almost a certaintv and that it usuallv can be managed bl' 
relativelv const:lVativt: means shuuld SCIVC as a deterrent to the cx~essiv~ 
usc of measures that may cause fatal bone marrow depressiun .... It is 
also conceivahle that the avoidance of a primary host-graft reaction bv 
thest: means lexcessive immunmupprcssionj would prevent the adaptive 
process. 
At the time this hellwether series was compiled hetween the 
autumn of 1962 and April 1%3. the only other active clinical 
transplantation programs in the United States were in Richmond 
(directed hy David Hume) [110] and at the Peter Bent Brigham 
Hospital in Boston (directed hy Joseph Murray and John Merrill) 
[Ill]. The important earlier program of Willard Goodwin at 
UCLA (see earlier [9,1]) had heen closed hecausc all of the 
recipients died in less than 5 months. 111 Europe. TBI brietly 
remained the prderreu treatment at the long-standing Paris cen· 
ters of Jean Hamhurger and Rene Kuss. whereas Michael Wood-
ruti' of Edinhurgh had hegull testing azathioprine [112]. 
The results in the Colorado series. and more importantly an 
exact description of the strategy that had been used to induce 
variable degrees of incomplete tolerance (Table ~FK created a 
surge of new activity. Within 12 months new kidney transplant 
centers proliferated in North America and Europe. Most of these 
s<.:cond-generation programs remain in oper:ttion today. 
The ohservations in the original kidney recipients were 
promptly contirmed. However. the proposed explanation for these 
,uccesscs (i.e .. grail alteration plus loss of specitic immunologic 
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Table 4. Empiric therapeutic dogma of immunosuppression. 
Ingredients of strategy 
Baseline therapy 
Secondary adjustments of prednisone dose. or 
antilymphoid agents" 
Case-t~-case trial (and potential error) of 
weaning 
Baseline agent 
Azathioprine" 
Cvclosporine 
Tacrolimlls 
"Alom: or with prophylactic prednisone. Equivaknt n:sults were ob-
tained with cyclophosphamide instead of azathioprine [I D. Ilol]. 
I>lnitially used for prophylactic "induction" [115]. 
responsiveness [31]) was controversial and remained so for the 
next three decades (see Allograft Acceptance versus Acquired 
Tolerance. below). Except for reports from the University of 
Colorado. the term "tolerance" was studiously avoided from 1%4 
onward when referring to the long-surviving dogs and human 
kidney recipients produced by the end of 1963. 
The article most often quoted as contravening tolerance was 
that of Murray et al. [106] despite the fact that. as the authors took 
pains to make clear. the evidence in their report was inconclusive 
and involved only two canine experiments of a potentially crucial 
nature. The two long-surviving dogs had been given renal ho-
mografts 9 and 18 months previously and had been treated for 
most of these times with one of the purine analogues. Renal 
function was deteriorating at the time contralateral kidneys from 
the original donors were transplanted. The second organs were 
rejected after 23 and 3 days. respectively. as would he expected. 
In commending Murray's 1964 report and conclusions. Me-
dawar wrote [116JI: 
There is. however. something special about renal homografts. as JMichaelJ 
Woodruffs appraisal in this volume makes very clear. A synoptic survey of 
more than 1000 renal homografts in dogs carried out bv Murrav and his 
colleagues [Murray. Ross Shiel. Mosele~vK Knight. McGavic & Dammin. 
1964][ J06] has shown that foreign kidneys do sometimes become accept-
able to their hosts for a reason other than acquired tolerance in the 
technical sense .... There has been an adaptation of some kind-a pos-
sihility Woodruff has long urged us not to overlook [117. 11 H] thougll there 
is no reason to believe it an antigenic adaptation. 
One possible explanation is the progressiv..: and perhaps very extensive 
r<:plac<.:ment of the vascular endothelium of the graft bv cndoth<.:lium of 
host origin. a process that might occur insidio-usly aild imperceptiblv 
during a homograft reaction weakened by immunosuppressive drugs .... 
Another possibility. raised by R.Y. CaIne Jthough not mentioned by him 
in his contribution to this volume I is the laying down of a protectiv..: coat 
of host antibody on the endothelial inm:r surface of the graft-an expla-
nation which would classifv the plll:nomenon under the general heading of 
"enhancemcnt.·· 
These disclaimers notwithstanding. the commonality of the re-
jeetion barrier for different organs was self-evident. as was the 
likelihood that the means of inducing acceptance of one organ 
could be used for all the others [119J. There also was evidence 
from earlier experiments that a liver allograft could protect other 
donor tissues and organs. It had been noted in 1%2 that intestine 
and pancreas had little histopathologic evidence of rejection in 
untreated canine recipients if they were components 01 multivis-
ceral allografts that also included the Ii\'er [120J. These observa-
t ions were contirmed J() years later in a rat version 01 the same 
multivisceral procedures [121. 1221· 
'Original numhers in the 4uolI: ha,'e heen changed to those of curn:nt 
rdcrencc liSt. The 4uotaUlln IS llth<':fwl,e \crh'\llm. 
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Most convincingly at an experimental level. it was shown in 
I t}64 that orthotopic canine liver allografts could induce and 
maintain their own acceptance far more frequently and perma-
nently than renal allografts. even with a treatment course of 
azathioprine as short as 4 months [123, 124]. Soon thereafter. 
spontaneous engraftment was demonstrated after liver transplan-
tation in untreated outbred pigs [125-129]. many of which passed 
through self-resolving rejection crises [128, 130. 131 J. 
Thus it already was clear by 1964-1965 that the liver is the most 
to\erogenic organ. During the late 1960s and early 1970s. CaIne, 
Zimmerman. and Kamada formally proved that the liver toleriza-
tion extended to other donor tissues transplanted at the same time 
or later. first in untreated outbred pigs [132] and then without 
immunosuppression in selected rat strain combinations [133-135]. 
Although they were important. the experimental studies with 
hepatic allografts only affirmed the conclusion reached with the 
1962-1963 experience in clinical renal transplantation suggesting 
that all organs were capable of inducing tolerance. As with liver 
allografts. the self-induction of donor-specific tolerance by heart 
and kidney allografts without the aid of immunosuppression was 
later demonstrated by Corry et al. [136J and Russell et al. [137] in 
selected mouse strain combinations. 
The key mechanism of kidney-induced allograft acceptance was 
suggested as early as 1964 to he clonal exhaustion [138J. This 
concept was developed more fully for liver allografts in Figure 2. 
published in 1969 [139]. Induction of the activated clone by al-
loantigen was depicted via host macrophages rather than by an-
tigen-presenting dendritic cells. which would not be described 
until 1973 [140]. In the text accompanying the figure. it was 
pointed out that exhaustion and deletion of an antigen-specific 
clone had been postulated by Schwartz and Damesehek as early as 
1959 to be the mechanism of the tolerance to heterologous pro-
tein induced in rabbits with the aid of h-MP [94]. In addition. 
Simonsen had suggested in 1960 that clonal exhaustion induced by 
allogeneic splenocytes could lead to the acquisition of tolerance in 
adult animals in the absence of immunosuppression (I ~ I J. 
The error of making a semantic distinction between tolerance 
and graft aCCl:ptance was understandable. The picture that had 
cmerged from the remarkahle acwmplishments with clinical kid-
ney transplantation between January 1959 and the spring of 1963 
was not a product of new insight in immunology. Instead. success-
ful organ transplantation was an intellectually troubling and inex-
plicable violation of the immunologic rules of the time. The 
revolution in immunology that had already begun and would 
continue for the next third of a century did little to change this 
vtew. 
The Burnet antihody hypothesis of clonal selection (see earlier 
[f~zF was validatcd and extended to cellular immunity by the late 
1950s [142-144J. but it had minimal intluence on the clinical 
development of transplantation. Neither did many other kcy ad-
vances in immunology which were either contemporaneous with. 
ur came after. the rise of organ transplantation. The role of the 
thymus in the ontology of the immune system and in the postnatal 
immune function of rodents was discovered in 1961 (by Jacques 
Miller [145. 14(1). However. thymectomy in humans did not sig-
nificantlv alter either the early or late course of kidney transplant 
recipients [147. 14XI. Lymphocytes were not formallv assigned a 
functionunul I%J (by James Gowans [149.150]). although work-
~Drs in transplantation were awarc several years earlier that these 
mononuclear leukocytes \\ere the cellular agents of allogralt re-
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Fig. 2. 1969 hypothesis of 
allograft acceptance by clonal 
exhaustion. Antigen presentation 
was depicted via the macrophages 
rather than bv the dendritic cells 
(which had n~t vet been 
described). A gap in this 
hypothesis was the failure to 
stipulate the location of the 
immune activation. (From Starzl 
[139]. with permission.) 
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Fig. 3. Diffusion chamb<:r us<:d in studi<:s by Algire et al. [151). from 
which tlll:y cllnciud<:d that lymphocytes w<:r<: the cellular agents of allo· 
graft rejection. (From Slarzl and Blitz [1J). with permission.) 
jection [1.1. 151. 1521 (Fig. 3). By the time the distinction was 
clearly established between T and B lymphocytes. transplantation 
was an established specialty of clinical medicine. 
Thus [he ascension of organ transplantation came as a surprise 
to most immunologists. Even as the clinical advances had begun to 
unfold. Burnet [I ~~z had written in the New Englund lvumal or 
Medicinc that "much thought has been given to ways by which 
tissues or organs not genetically and antigenically identical with 
the patient might he made to survive and function in the alien 
environment. On the whole. the present outlook is highly unfa-
vorable [0 succcss:· Pessimism also was deeply ingraincd in con-
ventional practitioners of medicine. Well into the 1l)6()s editorials 
were published in major clinical journals questioning hoth the 
inherent feasibility and the ethnical basis ot transplantation pro-
cedures 1153]. As a consequence. transplantation acquired a ren-
egade Imagc. a burdcn soon compounded by dilticulties in extend-
HOST DEFENSE 
IMMUNOSUPPRESSION 
(peak at rejection crisis) 
Bacteria 
Bacteria 
Fig. 4. Possible mechanisms of simultaneous loss of host reactivitv III 
specific strains of ~ndllgenous bacteria and to the alien renal tissue. (F'rum 
Starzl et al. [15-1). with permission.) 
ing its reach to the replacement of vital organs other than thc 
kidney. 
One dikmma. as it was perceived at the time. is shown in Figure 
~ [1541. It was kared that chronic drug immunosupprcssion pow-
erful enough to prevent organ allograft rejection would render the 
recipient hopelessly vulnerable to indigenous and environmental 
pathogens. Early reports of infectious disease complications in the 
early Colorado recipients [1551 and elsewhere gave warning that 
dire consequences might. in time. bc in store for all recipients. It 
~dso was suspected that immunc surveillance to tumors would be 
eroded. a possibility that was veri tied but shown to be manageahk 
by IlJ6H [156-1 :is]. 
.\utopsy studies in faikd clinical cases revcakd a typical pat-
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tern. Infections for which specific antibiotics were available could 
be largely controlled. However. opportunistic microorganisms of 
normally low pathogenicity were overrepresented and appeared at 
autopsy to be the main cause of death [159]. Of these infections. 
cytomegalovirus (CMV) was the most common and most lethal. 
The presence of Pneumocystic carillii as a co-infection with CMV 
[160] premonitored the lethal role of this combination of infec-
tious agents in the AIDS epidemic in the nontransplant popula-
tion that lay two decades ahead. 
Maturation of Transplantation 
Although it was entirely empiric. the practical framework re-
quired for the maturation of clinical transplantation was essen-
tially complete by the end of 1963. Without knowing either the 
nature of the normal immune response or the way in which it had 
been subverted, it had been learned how to redirect the immune 
response reliably with the aid of immunosuppression. Surgical 
(see above) and preservation techniques (see later) had been 
developed for transplantation of all of the organs and are used 
currently wi th only minor modifications. Yet the field of organ 
transplantation stalled and now entered a phase that was euphe-
mistically tcrmed "consolidation." The reason was the failure to 
find improved means to exploit the principles for controlling 
rejection that had been established with azathioprine and pred-
nisone (Table 4). 
Improwd ImmunoslIppression 
Anti(vmp/lOid Strategies. Between 1963 and 1979 the only signifi-
cant advance in clinical immunosuppression was the introduction 
in 1966 of heterologous antilymphocyte globulin (ALG) [115. 
162]. This was a logical extension of Gowan's demonstration of 
the immunosuppressive clfects of lymphoid depletion with tho-
racic duct drainage (TOO) in rats [149. 150J. In fact. Woodruff 
and Anderson showed that TOO and antilymphocyte serum 
(ALS) had additivc effects [1(3). 
Clinically used by Franksson and Blomstrand in 1963 to treat 
kidney recipients in Stockholm [164J, TOO is an approach that 
rcsurfaced periodically during the next two decades (summarized 
in [165]). Conditioning with TOO prior to transplantation clearly 
reduccd the frequency and vigor of kidney rejection. but 30 days 
of pretrcatment was required in humans [165. 166J compared to 
the 5 days in Gowan's rats [149. 150J. However. the inconve-
nience. complexity. and expense of TOO precluded widespread 
usc [H16J. For the same reasons. total lymphoid irradiation (TLI) 
[1671. which also was an clfcctive mt:ans of lymphoid depletion but 
with the disadvantage of not being quickly reversible. did not have 
a lasting impact on clinical transplantation [I M\. 1(9). 
In contrast. ALG was a major lkvelopment for two rt:asons. 
First. it was a critical factor in the emergence of extrarenal organ 
transplantation. Second. it was a prototype drug from which nu-
merolls variations evolved. The concept of mitigating cellular 
immunity with heterologous antibodies had been proposed by Ilya 
Metchlllkotl at the end of the nineteenth century [170J and was 
revitalized by Inderbitzen [171 J and Waksman et al. [InJ before 
Woodrutf and Anderson [163J. Levey and Medawar [173J. Mo-
naco. Wood. and Russell [174. 1751. and other surgeons recog-
nized its potential role in clinical transplantation. 
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In most of the animal investigations up to 1963 the anti-lym-
phocyte antibodies were raised in rabbits; and raw ALS was 
administered to all recipients. In preparation for clinical trials, 
horse anti-dog ALS was prepared. and the active moiety was 
refined from the gamma globulin [162]. After the product was 
shown to inhibit or reverse rejection in the canine kidney and liver 
transplant models [I 15], comparable horse anti-human ALG was 
produced from the serum of horses immunized with leukocytes 
separated from human lymphoid organs (lymph nodes. spleen. 
thymus) [162]. 
The first clinical trial of ALG began in 1966. Daily injections 
were given to kidney recipients for 1 to 4 weeks postoperatively as 
a short-term adjunct to continuous azathioprine and prednisone 
[115]. After encouraging results were obtained in the kidney trial, 
liver transplantation was resumed, with long survival of several 
patients. The successful liver replacements during the summer of 
1967 [20] expanded the horizon of transplantation to the other 
vital extrarenal organs. Within the succeeding 27 months. heart 
[21, 22], lung [23]. and pancreas [24] transplantation was accom-
plished. using variations of the treatment shown in Table 4. As 
had happened with kidney centers in 1963, a wild proliferation of 
extrarenal (particularly heart) programs followed. However. al-
most all of them closed within the next 2 years because of an 
overwhelming failure rate. 
Polyclonal ALG was never used in more than about 15% of 
kidney transplant cases reported to registries up to the early 
1980s, in part because it was in no sense a standardized drug such 
as azathioprine or prednisone. Although the use by Najarian and 
Simmons [176] of known numbers of cultured human Iympho-
blasts for accurately timed horse immunization improved the 
predictability of the ALG potency, batch-to-batch variations in 
potency remained problematic. "Antibody therapy" came of age 
with monoclonal antibodies, whose production was made feasible 
by the hybridoma technology of Kohler and Milstein [177]. OKT3. 
the first-generation monoclonal antibody, was directed at all T 
lymphocytes [178J. Subsequent antibody preparations. which in-
clude less immunogenic humanized "hybrids." have been directed 
at discrete targets such as T cell subsets. adhesion molecuks. and 
T cell or interleukin-2 receptors. However. when these agents arc 
used. the "induction" strategy has been essentially tht: same as 
with the original crude ALG. 
(Vc/Op/lOsp/w/1lide. Although the experience during this middle 
cra, defined by the first triple-drug regimen. demonstrated the 
feasibility of transplanting the vital extrarenal organs. it also 
indicated that further progress would require better baseline im-
munosuppression. Substitution of the alkylating agent cyclophos-
phamide for azathioprine was such an cti'ort [1131. The character· 
istic cycle of immunologic confrontation and resolution leading to 
graft acceptance was no different with this drug than with azathio-
prine-based therapy. When the results with kidney and liver trans-
plantation were almost identical to those using azathioprine but at 
a higher price of complications. the trials were discontinued I 1 141. 
Although cyclophosphamide therapy became a footnote in the 
history of organ transplantation. it continued to playa role in 
bone marrow transplantation. 
(\·c/ospOrilll'. Another decade would pass hefore the grt:ater po-
tency of eyc\osporine would make transplantation of the liver and 
other cadaveric organs (including the kidney) a reliable service. 
I 
! 
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Cyclosporine. an extract from the fungi Cylindrocarpon lucidWll 
and Trichodenna polysporum. was discovered by Dreyfuss et al. 
[179J and characterized biochemically by Ruegger et al. [180J and 
Petcher et aL [181]. It was shown to be immunosuppressive by 
Borel et al. [182-184] with multiple test systems including skin 
allotransplantation in mice. rats. and guinea pigs. 
The drug depressed humoral and cellular immunity and had a 
preferential and quickly reversible action against T lymphocytes. 
Unlike azathioprine and cyclophosphamide. these effects were not 
accompanied by bone marrow depression or other prohibitive 
organ toxicity. The ability of cyclosporine to prevent or delay 
rejection of the heart, kidney, liver. or pancreas was promptly 
shown in rats, rabbits. dogs, and pigs by Kostakis et al. [185J. 
Caine [186-188]. and Green and Allison [189] and their associ-
ates. There was no hint in these preclinical studies that nephro-
toxicity would be the dose-limiting factor in human trials. 
The toxicity profile of cyclosporine became evident in Calne's 
initial evaluation of cyclosporine in human recipients of 32 kid-
neys. 2 pancreases. and 2 livers reported during 1978-1979 [190. 
191]. The ability of the drug to prevent rejection. alone or in 
combination with myelotoxic drugs. exceeded anything previously 
seen. However. the requisite overdosage caused multiple serious 
side effects: nephrotoxicity, neurotoxicity, diabetogenicity. a 10% 
incidence of B cell lymphoma. and cosmetic changes (gingival 
hyperplasia, facial brutalization. and hirsutism). 
When cyclosporine in lower doses was combined with pred-
nisone in the treatment algorithm shown in Table 4, the prognosis 
of cadaver kidney recipients was improved [192]. and transplan-
tation of the liver [193]. heart [194, 195]. and lungs [196] was 
brought to the level of a practical clinical service. Recapitulating 
the aborted avalanche of 1967, many new extrarenal programs 
appeared. joining the five extant liver centers [Denver (from 
1963). Cambridge (1968), Hannover (1972), Paris (1974), Gro-
ningen (1977) I and the single remaining heart program [Stanford 
(from 1(68)). This time, most of the programs flourished. 
Tacrolimlls. Cyclosporine was the unchallenged baseline immu-
nosuppressant for all varieties of transplantation until it was 
shown in 1989 that intractably rejecting liver allografts could be 
regularly rescued by replacing cyclosporine with tacrolimus [1(7), 
an extract of Streptomvces tsukabaensis discovered by Kino and 
Goto et al. [198J. Tacrolimus was tested initially in a rat cardiac 
transplant model by Ochiai et al. [199) and soon thereafter by 
Murase et al. in rats [200. 201) and by Todo et al. in dogs [202. 
203] and subhuman primates [203. 204]. 
In addition to numerous confirmatory reports of its ability to 
rescue about 75% of intractably rejecting human liver allografts 
[205]. tacrolimus could salvage an equal proportion of rejecting 
hearts. kidneys. and other organs [2(6). [n virtually all such caSl!s. 
a switch back to cyclosporine was never made. Consequently. 
clinical trials using tacrolimus primarily Wl!rl! begun [206-2081. 
By early 1990 more than 150 liver. kidnl!y. hl!art. and heart-lung 
recipients had been treated from the time of transplantation with 
immunosuppression based on tacrolimus rather than cyclosporine 
[209]. It was learned from this experience that the three major 
side effects of the drug (nephrotoxicity. neurotoxicity. diabetoge-
nicity) were comparable to those of cyclosporine. Hypertension 
and hyperlipidemia were less common than in historical CYclo-
sporinl! controls. The cosmetic l!tfects of eyclosporinl! were not 
seen (Table 5). 
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Table 5. Nonimmunologic profile. 
Tacrolimus 
Factor (FK 506) Cyclosporin A 
Nephrotoxicity ++,/ ++ 
Neurotoxicity + + 
Oiabetogenicity + + 
Growth effects 
Hirsutism () +++ 
Gingival hyperplasia 0 ++ 
Facial brutalization 0 + 
Hepatotrophic effects ++++ +++ 
Gynecomastia 0 + 
Other metabolic effects 
Cholesterol increase if ++ 
U ric acid increase +~ ++ 
Reprinted from Starzl et al. [214]. copyright 19(H. with permission 
from Elsevier Science. 
+: best: + + + +: worst (all dose-related). 
"Less hypertension. 
hOespite this observation in humans [161] Van Thiel observed an 
increase in cholesterol synthesis and serum concentration in rats (personal 
communication. August 1. 1990). 
The effective use of both cyclosporine and tacrolimus required 
the same pattern recognition and therapeutic response that have 
guided organ transplantation since its inception (Table 4). The 
dose ceilings of the four widely used baseline immunosuppres-
sants were imposed by toxicity: myelotoxicity for azathioprine and 
cyclophosphamide and the more complex side effects shown in 
Table 5 for cyclosporine and tacrolimus. The dose floors were 
revealed by the breakthrough of rejection. Because none of the 
four drugs could be used alone. they had to be incorporated into 
"cocktails" in which the requisite doses of the individual drug 
constituents were determined on a case-to-case basis by trial and 
error. Dose-maneuverable prednisone has remained a constant 
for 36 years, but steroid dependence declined with the more 
potent baseline agents. 
The lead organ for azathioprine was the kidney. The develop-
mental responsibility for cyclosporine was shared by the kidney 
and liver. and the liver bore the principal burden for tacrolimus 
[197,205.207,209-213]. Progress with one kind of organ allograft 
inevitably meant progress for all. Thus survival of each kind of 
organ graft rose in the same three distinct Il!aps between 1962 and 
1998 (Fig. 5). With tacrolimus. the intestine was no longer a 
"forbidden" organ [214-216]. 
Ripple Elfect 
Orgall Procllremelll alld Prcsen'ati0l1 
The sudden arrival of clinical kidney transplantation during 1%2-
1963 was so unexpected that littk collateral research or other 
formal preparation had been made to preserve organs. Although 
kidneys were successfully transplantl!d in the pioneer identical 
twin cases despite protracted periods of warm ischemia. thl! mat-
uration of clinical transplantation could nO! procel!d without ef-
fective organ conservation. This was accomplishl!d at first with 
total body hypothermia of living voluntl!er kidney donors [217] 
using methods dl!velopl!d by cardiac surgeons for open heart 
operations [218]. In thl! experimental lahoratorv. Lillehei et al. 
[41l] simply immersed the exclsl!d intestlnl! in iCl!d saline before its 
Starzl: History of Clinical Transplantation 
100 
-::!2. 0 80 
~ 
> 60 .:;; 
~ 
::J 
(j) 40 
C 
Q) 
ca 20 
a.. 
0 
100 
-::!2. 0 80 
~ 60 
> ~ 
c75 40 
-
-; 
~ 20 (!) 
• AZA (n=168) 
• eYA (n=1835) 
• TAe (n=1391) 
0 1 2 3 4 5 
Time after Transplantation (years) 
• AZA (n=190) 
• eYA (n,,2416) 
• TAG (n=1582) 
769 
\ 
Fig. 6. Technique of extracorporeal perfusion with a heart-lung machine 
described by Marchioro et al. [2201. Catheters are inserted via the femoral 
vessels into the aorta and vena cava as soon as possible after death. The 
extracorporeal circuit is primed with a glucose or electrolyte solution to 
which procaine and heparin are added. The cadaver is thus anticoagulated 
o +-----r----r----....... ---....,.------. with the first surge of the pump. Temperature control is provided by the 
o 1 2 3 4 
Time after Transplantation (years) 
5 heart exchanger. Cross-damping the thoracic aorta limits perfusion to the 
lower part of the body. (From Starzl [2(lJl. with permission.) 
Fig. 5. Three eras of orthotopil: liver transplantation at the Universities 
of Colorado (1lJ63-llJXO) and Pittsburgh «(lJXI-IlJ93). dt.:fined by azathio-
prine-. cvclosporine-. and FK 506 (tacrolimus)-based immune suppres-
sion. The same stepwise improvement was seen with all organs. Top. 
Patient survival. Bottom. Graft survival. The rate here was about 10% 
lowt!r than that for patient survival in both tht! cyclosporine (llJXO-IlJX9) 
and tacrolimus eras (19X9-IYlJ3) because of effective retransplantation. an 
option that did not exist previously. AZA: azathioprine: CYA: cyc!ospor-
int!: TAC: tacrolimus. 
autotransplantation. a method also used by Shumway when de-
veloping experimental and clinical heart and heart-lung transplan-
tation [45-471. Thus the principle of hypothermia was understood 
at an early time. although not efficiently applied. 
The first major innovation in hypothermia was in the labora-
tory. when canine liver allografts Were cooled by infusion of 
chilled fluids into the vascular bed of hepatic allografts via the 
portal vein [431. Before this time. dogs after liver transplantation 
was almost never survived. whereas afterward sUCCess hecame 
routine. In a logical extension to clinical kidney transplantation. 
the practice was introduced in 1963 of infusing chilled lactated 
Ringer's or low-molecular-weight uextran solutions into the rcnal 
artery 01 kidney grafts immediately after their removal [2191. 
Todav. intravascular woling is the first step in the preservation 
llf all whole-organ grafts. For cadaver uonllrs. this is most often 
done in situ hy some variant of the technique descrihed hy Mar-
chioro et al. 12201 (Fig. 0). This methou for the continuous hypo-
thermic perfusion of cauaveric livers anu kiuneys was useu clini-
cally long before the accepwnce of brain death. Ackerman anu 
Snell 122 II anu Mcrkel. Jonasson. allu Bergan (2221 popularized 
the simpler core cooling of cadavers with cold electrolyte solutions 
infused into the distal aorta. 
Organ ProclIremellt. Until 1981 transplantation of the extrarenal 
organs was an unusual event. By late 1981. however. it had he-
come obvious that liver and thoracic organ transplant proceuures 
were going to he widely used. A method of multiple organ pro-
curement was required by which the kidneys. liver. heart. and 
lungs or various combinations of these organs could he removed 
without jeopardizing any of the individual organs. "Flexible tech-
niques" were developed [223. 2241 that were quickly adopted 
worldwide. With these methods all organs to be transplanted are 
cooled in situ. rapidly removed in a bloodless field. and dissected 
on a back table. The sharing of organs from a common donor hy 
recipient teams from widely separated centers became routine by 
the mid-llJ80s. 
Er Vim Pel1ilsicJIl. Extension of the safe period after initial cool-
ing has followed one of two prototype strategies. developed with 
kidneys or livers and applied secondarily to other organs. One 
approach that was extensively evaluated by Alexis Carrel and the 
aviator Charles A. Lindberg was to simulate normal physiologic 
conditions with ex vivo pcrfusion techniques [2251. This concept 
was modified hy Ackerman and Barnard [2261. who proviueu the 
isolated organs with a continuous low-tlow renal arterial circula-
tion using a perfusate primed with hlood and oxygenated within a 
hyperharic oxygen chamber. This tcehnique also permittcu goou 
preservation of hepatic allografts for as long as a Jay 12271. 
However. the complexitv of thc me thou precluueu its general 1I,e. 
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Elimination of the hemoglobin and hyperbaric chamber com-
ponents by Belzer et al. [228] resulted in satisfactory kidney 
preservation for up to 2 to 3 days. The asanguineous perfusion 
technique eventually was abandoned in most kidney transplant 
centers when it was learned that the quality of 2-day preservation 
was no better than with the simpler "slush" methods (see below). 
Nevertheless, it is expected that refinement of perfusion technol-
ogy will someday permit true organ banking. 
"Slush" Preservation. With the so-called static methods, fluids of 
differing osmotic, oncotic, and electrolyte composition are infused 
into the allograft before placing it in a refrigerated container [229, 
230]. The solution described by Collins, Bravo-Shugarman, and 
Terasaki [229] (which resembles intracellular electrolyte concen-
trations) or modifications of it were used for almost two decades. 
Renal allograft preservation was feasible for 1 to 2 days, long 
enough to allow tissue matching and sharing of organs over a wide 
geographic area. Experiments with hepatic allografts by Benichou 
et aJ. [231] using the Collins-Terasaki solution and by Wall et al. 
[232] with the plasma-like Schalm solution led directly to liver 
sharing among cities but with a time limitation of only 6 to 8 
hours. 
Introduction of the University of Wisconsin (UW) solution to 
liver transplantation by Belzer, Jamieson, and KalayogJu [233, 
234] was the first major development in static preservation since 
the Collins-Terasaki solution [235]. The superiority of the UW 
solution for preservation of the kidney and other organs was 
promptly demonstrated in experimental models and confirmed in 
clinical trials [236-241]. The UW preservation doubled or tripled 
the time of safe preservation of the various allografts. making 
national and international sharing of most organs an economic 
and practical objective. 
Life Sciences 
While occupying its own unique niche, transplantation has drawn 
from and in turn enriched all of the other basic and clinical 
scientific disciplines. Aside from changing the philosophy by 
which organ-defined specialties of surgery and medicine arc prac-
tices. transplantation grew parallel with and contributed in a 
major way to advances in immunology, pharmacology, oncology 
(e.g., the role of tumor immune surveillance [158.242]), infectious 
disease. intensive care, and anesthesiology. Study of each of the 
allografts has yielded an organ-specific harvest of special infor-
mation. Examples include a better understanding of diabetes 
mellitus with pancreas transplantation and the effects of denerva-
tion on cardiopulmonary function with heart and lung transplan-
tation. 
The liver became the key organ in unmasking the secrets of 
acquired tolerance because of its large content of immunocom-
petent leukocytes (see earlier and Allograft Acceptance versus 
Acquired Tolerance. below). In addition. the functional complex-
ity of the liver and its metabolic interactions with other abdominal 
viscera have made hepatic transplantation a "mother lode" for 
physiologic studies [243]. 
During the course of determining the optimal revascularization 
of auxiliary livers transplanted to ectopic sites or to the normal 
location [43. 244. 245], it was found that endogenous insulin is a 
liver growth factor [246. 247]. the first such hepalOtrophic factor 
to be identified. Using transplantation-derived models. a family of 
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other molecules was delineated with insulin-like hepatotrophic 
properties [241\]. Eventually the gene was discovered that ex-
presses one of them (augmenter of liver regeneration) [249-251]. 
The hepatotrophic factors. most of which are cytokines [e.g., 
hepatocyte growth factors (HGF) J. rcgulate liver size, structure. 
regeneration. and metabolic homeostasis. 
Studies of hepatotrophic physiology led directly or indirectly to 
liver rcplacement for cure of more than two dozen hepatic-based 
inborn errors of metabolism [252J, including familial hypercholes-
terolemia [73, 74J. The role of hepatic transplantation in first 
suggesting, and then proving, that the liver governs cholesterol 
metabolism has been described elsewhere [73, 74, 252,253]. Elu-
cidation of the cellular and molecular mechanisms was rewarded 
by bestowal of the 1985 Nobel Prize to Brown and Goldstein 
(Table 2). 
Immunologic Screening 
The importance of the genetically determined major histocom-
patibility complex (MHC) in determining the immune response to 
allografts was evident from investigations by George Snell in 
inbred mice [254], which in turn derived from the work of Peter 
Gorer [255]. However, the information was not clinically applica-
ble. Thus immunologic screening of donors and recipients was not 
done during the volatile developmental period of 1959-1963 [1]. 
The possibility of tissue matching did not begin to emerge until 
the discovery by Dausset of the first human leukocyte antigen 
(HLA) in 1958 [256] and the discovery that same year by Van 
Rood et al. [257] of anti-leukocyte antibodies (soon shown to be 
HLA-directed) in the sera of pregnant women. The report in 1964 
by Terasaki and McClelland [258] of the microcytotoxicity test. 
with which HLA antigens could be detected serologically in 
minute quantities of sera. was a critical development in moving 
forward with the classification of the antigens. 
Crossmatch Principle 
As it turned out. the greatest impact of pretransplant tissue 
matching has been the prevention of hyperacute rejection by 
observing ABO compatibility guidelines and routine use of the 
cytotoxicity crossmatch. 
ABO Compatibilitv. Hyperacute rejection was first observed more 
than 30 years ago when ABO-mismatched renal allografts were 
transplanted into patients who had preformed anti-graft ABO 
isoagglutinins [54. 259J. After kidneys were lost on the operating 
table. arteriograms of the infarcted organs showed nonfilling of 
the small vessels. correlating histopathologically with widespread 
thrombotic occlusion of the microvasculature. It was concluded 
that high-affinity isoagglutinins in the recipient serum had bound 
to A or B antigens in the graft vessels and parenchymal cells. This 
was consistent with the rapid changes in recipient isoagglutinin 
titers that followed organ revascularization. The guidelines for-
mulated from this experience [54. 259] were designed to avoid 
such antibody confrontations (Table I). 
The ABO rules also apply to heart. liver. and other organ 
transplantation. As was originally observed in 11)63 with ABO-
mismatched kidneys. however. [54. 259]. not all organs placed in 
the hostile environment of anti-graft isoagglutinins meet the same 
fate. In fact. the longest continuously functioning renal allograft in 
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Fig. 7. Contemporaneous host-versus-graft (HVG) and graft-versus-host 
(GVH) reactions in the two-way paradigm of transplantation immunology. 
Following the initial interaction. the maintenance of nonreactivity of each 
leukocyte population to the other is seen as a predominantly low grade 
stimulatory state that may wax and wane. rather than a deletional one. 
the world [109] is a B+ kidney donated to a then 38-year-old A + 
male recipient by his younger sister on January 31, 1963. In 
addition, it was learned at an early time that the liver is more 
resistant to antibody attack than other organs [260]. 
In histocompatibility studies in which human volunteers were 
sensitized with purified A and B blood group antigens, causing 
variably increased titers of isoagglutinins. Rapaport et al. [261] 
showed accelerated or hyperacute (white graft) rejection of ABO-
incompatible skin grafts transplanted to recipients with high titers. 
This completed the circle of evidence indicting anti-graft antibod-
ies as the precipitating cause of hyperacute organ rejection. 
With Non-ABO Antibodies. In 1965 hyperacute rejection of a 
kidney by an ABO-compatible recipient was reported for the first 
time by Terasaki et al. [262]. Terasaki's observation that the 
serum of the recipient of a live donor kidney contained preformed 
anti-graft Iymphocytotoxic antibodies was promptly confirmed in 
similar cases by Kissmeyer-Nielsen et al. [263) and others [264. 
2(5). Evidence of a cause-and-effect relation in the single first case 
was so clear that Terasaki recommended and immediatelv intro-
duced his now universally applied Iymphocytotoxic cro~smatch 
test [262. 2(6). 
It has been shown in presensitized animals and humans that 
antibodies. clotting factors, and formed hlood elements were 
rapidly cleared by the hyperacutely rejecting grafts [267, 2(8). 
Local fibrinolysis from the renal vein also was a consistent finding; 
and in exceptional cases there were systemic coagulopathies with 
disseminated intravascular coagulation (DIC) [269. 270). The 
findings are comparable to those seen with the Arthus reaction. 
inverse anaphylaxis. generalized Shwartzman reaction. and other 
models of innate immunity [265. 269. 270). 
Non-HLA antibodies such as anti-vascular endothelial cell an-
tibodies also have been associatcd with hyperacute or accelerated 
rejection [271. 272). The vulnerabilitv of extrarenal organs to this 
kind of rejection was ultimately demonstrated exp~rimentally 
[273-275) and c1inicallv. Although the liver was the most antibodv 
resistant [260]. it too ':;"as placed at increased risk by the presen'-
sitized state [276). Hyperacute rejection also has been docu-
mented in a small number of human organ recipients in the 
absence of detectable antibodies [265. 277). 
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Tissue Matching 
Historically, it was predicted that tissue matching would have to 
be perfected if long-term engraftment of tissues and organs was to 
succeed with any degree of reliability and predictability. The 
prophecy was immediately fulfilled with bone marrow transplan-
tation. in which anything less than a perfect or near-perfect match 
between the donor and recipient resulted in GVHD or rejection 
of the graft [27-30]. When similar expectations were not met in 
studies by Terasaki in kidney transplant recipients. the results 
initially were treated as a scientific scandal [278, 279]. When he 
later was proved to have been correct, Terasaki emerged as the 
father of HLA matching and as an enduring symbol of integrity. 
Terasaki's investigations began with a retrospective study of the 
influence of HLA matching on the quality of outcome of patients 
with long-surviving kidney allografts [280], followed by a prospec-
tive trial in live donor kidney recipients treated with azathioprine 
and prednisone. with or without adjunct ALG [281]. Consistent 
with the results in the classic skin graft investigations in nonim-
munosuppressed healthy volunteers by Rapaport and Dausset 
[282-284], HLA-matched allografts had the best survival and 
function. the least dependence on maintenance prednisone. and 
the fewest histopathologic abnormalities in routine 2-year post-
operative biopsy specimens [285]. Unexpectedly, however. no cu-
mulative adverse effect of mismatching in the kidney recipients 
could be identified. 
The equally imprecise prognostic discrimination of HLA 
matching in cadaver kidney transplant cases also was first recog-
nized by Terasaki (with Mickey et al. [286)) and has been evident 
in analyses up to the present time. With the large sample sizes in 
United Network for Organ Sharing (UNOS) and European data-
bases, virtually every comparison of the different levels of mis-
matching showed statistical significance. However. the absence of 
a large or consistent matching effect unless there is a perfect or 
near-perfect match has always been the same. In a recent study of 
more than 30.000 UNOS patients for whom optimal matches had 
been sought prospectively, approximately 85% of the cascs were 
in the two- to five-HLA mismatch spectrum. where I-year survival 
was clustered within 3%. Subsequent half-life projections there-
after were in the narrow spread of 9 to 11 years [287]. 
Terasaki's conclusions nearly three decades ago hreathed life 
into the still struggling field of liver, heart. and lung transplanta-
tion. It was a relief to know that the selection of donors with 
random tissue matching would not result in an intolerable penalty. 
A quarter of a century passed hefore it could be explained whv 
HLA matching was critical for bone marrow. but not orga~K 
transplantation (see the section that follows). 
Allograft Acceptance versus Acquired Tolerance 
During the Festschrift at Harvard honoring Paul Russell's retire-
ment in late November 1990. Norman Shumway told me and 
Leslie Brent about his textbook on thoracic transplantatIOn for 
which he wanted two chapters: one explaining the classic immu-
nologic tolerance exemplified by bone marrow transplantation 
and the other defining the presumably different mechanisms of 
whole organ allograft acceptance. On learning that I thought the 
two were the same in principle. Shumway assigned me the task of 
defending this opinion [288]. 
Evidence was obtained first from investigation of long-surviving 
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Fig. 8. Top panels. One-way 
paradigm in which transplantation 
is conceiv~d as involving a 
unidirectional immune reaction: 
host-versus-graft (HVG) with 
whol~ organs (left) and graft-
versus-host (GVH) with bone 
marrow or other fymphopoi~tic 
transplants (right). Bottom 
panels. Two-way paradigm in 
which transplantation is se~n as a 
bidirectional and mutuallv 
canceling immune reaction that is 
predominantly HVG with whole 
organ grafts (left) and 
predominantly GVH with bon~ 
marrow grafts (right). 
Organ Tx 
(1992) 
5l 
c 
I 
a: 
<1l 
c 
:J 
E § 
HVG 
Maintenance (3) 
----4 •• , .......... . ......................... 
.................................. (2 t) 
Leucocyte Depletion (4) 
Billingham/Brent 
Medawar 
(1953) 
Slavin/Strober (1977) 
IIdstad/Sachs (1984) 
Thomas (1987) Time 
Fig. 9. Continuum of chim~rism from th~ observations of lw~n in fr~~­
martin cattle to the diIcov~ry in 1992 of microchim~rism in organ recip-
Ients. 
human liver. kidney. and other organ recipients [31. 33.11\9-291 J and 
then from detailed confirmatory animal studies [292-2951. The oh-
seIVation that all J() patients tested had low level (micro) chimerism 
conformed perkctly \\itll the hypothesis heing tested that allograft 
acceptance ill\'olved not only chimerism hut a bidirectional immune 
reaClion (Fig. 7). The n.:lative strengths of the opposing immune 
reaClions foll,l\\lHg organ transplantation \\\.:re simply the reverse of 
Fig. 10. Four t:vents that occur in dose !I.:mpmal approximation when 
there is successful organ engraftm~ntK Top. DllUhk :.Jeutt.: clonal ~xhaus­
tion (\, 2) and subsequ~nt maintenanc~ donal exhaustion (.\). Bottom. 
loss of organ immunogenicity due to dt.:plt.:tion of tht.: graft's passengt.:r 
f~ukocytes (4). 
those following bone marrow transpl<mtation to the {,),toablated re-
cipient (summarized in [34. \09]). With this paradigm. it has been 
possible to view the historic miit:slOncs of dinical organ and bone 
marrow transplantation in a coherent way [351· 
Historicallv. an organ allograft had been envisioned as defense-
less and vul~erable -to imm-unologic attack in proportion to its 
histoincompatibilitv (Fig. S. top left). The same dllgma 111 reverse 
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Fig. II. Variable outcomes after infection with widl!lv disseminated non· 
cytopathic viruses (or other microorganisms) and an~logies (helow indi-
vidual graphs) to organ and bone marrow transplantation. The horizon-
(i.e., the host was the defenseless target) was the conventional 
view of bone marrow transplantation (Fig. ~I top right). Only two 
pioneer workers raised objections to the definition of transplan-
tation immunology in terms of a unidirectional immune reaction. 
In 1960-1901, Simonsen (141) and then Michie. Woodruff. and 
Zeiss [296) postulated that the two populations of immune cells in 
neonatally tolerant mice managed to coexist in a stable state hy 
becoming mutually nonreactive while retaining the ability to func-
tion collahoratively (i.e .. in a joint immune response to infection). 
Although this heretical suggestion resembled the concept sum-
marized in Figures 7 to II. the Simonsen-Woodrutr hypothesis 
was recanted in 1902 [2(7), ostensibly hecause no experimental 
support could he found for it. More importantly. however. it had 
heen advanced in a nonreceptive climate in which "group think" 
had already turned in a different direction. For the next 30 vears 
transplantation immunity and tolerance were conceived as prod-
ucts of unidirectional immune reactions of the kind that could he 
studied in vitro hy one-way mixed lymphocyte culture techniques 
descrihed hy Bain and Lowenstein [29X) and Bach and Hirschhorn 
[2(9). 
After chimerism was discovered in organ recipients in 1992-
1993 [32-34) it was recognized that the interaction of the coexist-
ing donor and recipient leukocyte populations was the common 
factor that underlay both the "acccptancc" induccd by whole 
organ allografts (Fig. S. hottom left) and thc tolerancc induced 
with bonc marrow (Fig. S. hottom right). This context closed the 
30-year intellectual gap between the fields of organ and bone 
marrow transplantation. Organ-associated chimerism then could 
hI! idl!ntitied in a continuum of classic tolerance models [5. II. 
167. 300-J021 beginning with the originalohservations hy Owen 
in frl!emartin cattlc (Fig. 9). 
OI1:ClI/ t.'lIgralillll'llt 
The immunocompetent donor Icukocvtcs in organ transplantation 
dre highly immunogl!nic. multilincag.: "passengl!r lcukocytes" of 
hone marrow origin (including stcm and dcndritic cells) that 
migrate preferentially to host Ivmphoid org,1I1S ,llld are replaced in 
tal axis denotes time. and the vertical axis shows the viral load (V. solid 
line). and the host immune response (IR. dashed line). 
the graft hy host cells. The result is widespread antigen-specific 
immune activation of the coexisting donor and recipient cells, 
each by the other. which proceeds in successful cases to variable 
reciprocal clonal exhaustion and then deletion (Fig. 7). 
Engraftment under clinical circumstances requires an umbrella 
of immunosuppression to prevent one ccll population from de-
stroying the other: but in some experimental models it occurs 
spontaneously (e.g .. after pig liver transplantation and in many 
rodent models). The "nullification" of thl! two arms explains thc 
poor prognostic value of HLA matching for organ wrsus bone 
marrow transplantation (Tahle 6) and the low incidence of 
GVHD following the cngraftment in noncytoahlated recipients of 
immunologically active organs, such as the intestine and liver. 
In addition to inducing clonal activation and exhaustion hy 
trafficking to host lymphoid organs, donor leukocytes that survive 
the initial dcstructive immunc reaction migrate secondarily to 
non lymphoid areas. where thev do not generate an immune rc-
sponse ("immune indifference"). From hcre they may "lcak" pe-
riodically to the host lymphoid organs and maintain clonal ex-
haustion, With clonal cxhaustion/delction and Immun.: 
indiffcrcnce in combination, hoth of which arc rcgulatcd hy the 
migration and localization of the antigen (34), the four interrl!-
lated events shown in Figure 10 must occur close together to have 
organ engraftment: douhlc acute clonal nhaustion. maintenancc 
clonal exhaustion (which frequently waxes and wanes), and loss of 
graft immul1ogl!tlieity as the organ is depleted of its passenger 
Icukocytes. 
BOllI.' MlII1"Ol\" TO/('/"(/IIC1.' 
Pretransplant cytoahlation renders the recipient susceptihlc to 
immune attack hy donor immune cclls (i.c .. GVHD). control of 
which frequently becomes the principal ohjective 01 immllnosup-
prcssion. rathcr than the prevcntion of rejection (Tablc 11). Be-
cause complcte dcstruction of host leukocytes is not possible with 
conventional dllSCS 01 cytoablation [3()31, the remaining cclls stim-
ulate an allllrcsponse hy mature or maturing donor T cdb. Nev-
ertheless. undl!r illlmunosllpprcssive treatmcnt. a weak hll~t-y"cr-
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Table 6. Differences between conventional bone marrow and organ 
transplantation. 
Factor Bone marrow Organ 
Recipient cytoablation" Yes No 
MHC compatibilitv Critical Not critical 
Principal complication GVHD Rejection 
Drug-free state Common Rare 
Term for success Tolerance .. Acceptance .. " 
GVHD: graft-versus-host disease: MHC: major histocompatibility 
complex. 
"All differences derive from this therapeutic step which in effect 
establishes an unopposed GVH reaction in the bone marrow recipient 
whose countervailing immune reaction is eliminated. 
"Also referred to as "operational tolerance." 
sus-graft reaction mounted by these few recipient cells and a 
para lid graft-versus-host reaction mounted by the donor bone 
marrow cdls may eventually result in reciprocal tolerance by 
deletion. These processes represent a mirror image of the events 
after organ transplantation (Fig. 8. bottom right). 
Relation to Infectiolls Disease 
NoncYlOpathic Microorganisms. Early workers in transplantation 
[304,305] recognized the resemblance of allograft rejection to the 
response against infections associated with delayed hypersensitiv-
ity, exemplified by tuberculosis. With the demonstration of the 
MHC-restricted mechanisms of adaptive infectious immunity by 
Doherty and Zinkernagel in 1973 [306-3()9], it became obvious 
that allograft rejection must be the physiologic equivalent of the 
response to this kind of infection. Microorganisms that generate 
such an adaptive immune response arc generally intracellular and 
have no or low cytopathic qualities [310]. 
Although M HC-restricted host cytolytic T lymphocytes recog-
nize only infected cells. elimination of all the infected cclls could 
disable or even kill the host. Consequently. mechanisms have 
evolved that can tempcr or terminate the immune response. al-
lowing both host allli pathogen to survive [310. 311]. They arc the 
same two mechanisms that allow survival of allografts (i.e., clonal 
exhaustiorlideletion and immune inditferenee) [34]. both of which 
arc governed by antigen migration and localization [34. 310. 311]. 
However. unlike the complex dual immune response of transplan-
tation. infectious immunity is essentially a host-versus-pathogen 
reaction. 
The analogies between transplantation and an infection with 
disseminated noncytopathie microorganisms can be exemplified 
by the common hepalitis viruses. as shown in Figure II [34. :110. 
:I II]. The pathogen (antigen) load may rapidly increase during the 
so-called latent pniod but then he dramatically and efficiently 
controlled by antigen-specific etrector T cells. which then subside 
(Fig. II. far left panel). The transplantation analogues arc acute 
irreversible I'CJection (or Intractable GVHD). Alternatively. a con-
tinuously high antigen load with an allligen-specitie immunologic 
collapse (Fig. I I. second panel) is equivalent to unqualitied ac-
ceptance ()f an allogratt. 
13etween these two extremes. the persistence of both the infec-
tious agent and a ... trong immune response results in serious 
immullopathology (e.g .. chronic active hepatitis with HBV or 
HCV infection) comp<lrahle t() chrome rejection after liver trans-
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Table 7. Effectors involved in response to cytopathic parasites and 
discordant xenografts. 
First line of defense 
Interferons 
Macrophag.es 
yeS T cdls 
Natural killer (:-.IK) cells 
B cells 
Nonspecific or less specific c!fcctors 
Complement 
Early interkukins 
Phagocytes 
plantation (Fig. 11. third panel) or uncommonly GVHD. The 
conditions in the cytoablated bone marrow recipient mimic those 
of an infection by microorganisms (e.g .. rabies and wart viruses) 
that avoid immune activation by not migrating through (or to) 
host lymphoid organs (Fig. 11. right panel) [34]. 
Because immunity and tolerance to alloantigens follow the 
same rules as the response to noncytopathic microorganisms [34]. 
it is not possible with current transplantation practices to induce 
tolerance to allografts on one hand without risking unwanted 
tolerance to pathogens on the other. In this context. the historical 
anxiety depicted in Figure 4 was correct. 
Cytopathic Microorganisms. There is no MHC-restricted safety 
valve for cytopathic microorganisms that are typically extracellular 
and generate the full resources of the innate and the adaptive 
immune system [310, 311). An uncontrollable innate immune 
response involving the effectors shown in Table 7 is provoked by 
discordant xenografts expressing the Gal a Gal epitope. an 
epitope that also is found on numerous cytopathic bacteria. pro-
tozoa, and viruses. 
The clinical use of such discordant animal donors requires 
changing the xenogeneic epitope to one that mimics a noncyto-
pathic protile or else eliminating the epitope [312]. Although 
chimpanzees and baboons do not express the Gal antigen. the 
clinical xenografts transplanted from these subhuman primate 
donors in 1963 [51. 52] ultimately were damaged by an uncontrol-
lable innate immune reaction. dominated by complement activa-
tion. Similar innate immune mechanisms were recognized during 
the 1960s to be responsible for the hyperacute destruction of 
ABO-incompatible allografts or allografts transplanted to presen-
sitized recipients (sec earlier) [265-270]. 
Self/NOli-self Discrimination 
Survival in a hostile environmcnt requires the ability to moullt a 
protective immune response while avoiding a reaction of the 
immune system against self. Transplantation has succeeded he-
cause it has not lethally eroded this capability. which dcpends 
ultimately on the governance of immunologic responsiveness nr 
unresponsiveness by migration and localization of antigen [34). 
Because the fetus possesses early T cell immune function [313-
315] the ontogenv of self/non-self discrimination during fetal de-
velopment can be explained by the same mechanisms as aequircd 
tolerance during later life. Autoimmune di ... eases then retleet 
unacceptable postnatal perturbations 01 the prenatally established 
localization of self antigens in nonlymphllid versus lymphoid com-
partments 134]. 
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Conclusions 
The lesson described in this chapter has been learned manv times 
before: All knowledge can be traced to its roots and ultim~tclv to 
a seed. For clinical transplantation. the historical beginning ~as 
'Vtedawar"s recognition that rejection is an immune re;ction.-Only 
two primary roots sprang from this seed. One was the demonstra-
tion by Billingham, Brent, and Medawar in 1953 that tolerance 
could be acquired by producing stem cell-driven hematolympho-
poietic chimerism [5]; this concept ultimately led to bone marrow 
transplantation in humans. The other root was the demonstration 
during 1962-1963 that kidney allografts could consistentlv self-
induce tolerance with the aid of immunosuppression [P~1z; all 
further developments in organ transplantation derived from this 
discovery. The assumption reached by consensus during the early 
1960s that the two roots reflected different immune mechanisms 
led to inadequate explanations of organ allograft acceptance and 
clouded the meaning of successful bone marrow transplantation. 
The false assumption, which promptly became dogma, saddled 
succeeding generations of scientists and clinicians with a context 
that precluded synthesis of a clarifying central principle of immu-
nology that could be applied to all transplant. much less nontrans-
plant. circumstances. After it was discovered in 1992 that organ 
recipients had persistent microchimerism, it was possible to see 
the essential commonality of organ and bone marrow transplan-
tation. to relate observations after these procedures to the im-
mune response to infectious diseases and neoplasms, and to ex-
plain the genesis of self/non-self discrimination. 
Resume 
La transplantation s'est dcveloppee griice a des agents 
immunosuppressifs de plus en plus puissants. a une amelioration 
des methodes de conservation des tissus et des organes, aux 
progres dans I'etude de I'histocompatibilite et aux n~mbreuses 
innovations dans les techniques chirurgicales. De par une 
combinaison de tels changements s'est ouverte la voie de grctfes 
de pratiquement to us les organes y compris la moe lie o;seuse. 
chez I·homme. Au plan bcaucoup plus fondamental. cependant. la 
reussite de la transplantation a etc lice a deux points 
determinants. Le premier a ete la reconnaissance par Billingham, 
Brent et Medawar en 1953 qu'il etait possible d'induire 
dCliberement une tolerance neonatale chimerique. Cette 
decouverte a permis, pendant les 15 'Ins suivants, de progresser 
rapidement vcrs la premiere greffe de moclle osseuse qui a eu lieu 
chez I'homme en 1968. Le deuxicme point a etc la demonstration 
au debut des annees 1960 que les allogretfes d'organes d'origine 
humaine et canine pouvaient indui;e par ell~s-mcmes -une 
tolerance il ['aide des medicaments immunosuppresscurs. A la tin 
de LlIlllee 1%2, .:ependant. on a wnclu. il tort, que lcs deux 
points en questions relevaient de mecanismes immuns ditfCrents. 
Cette erreur n'a pu etre corrigec que pendant les annees 19l)O. 
Dans cet article sur I'historique des transplantations. on resume la 
vaste litterature qui en est nee pendant cette periode de 30 ans. 
Bit!n que les progres empiriqucs soicnt admirablement bien 
documentes dans Ie domaine de la transplantation clinique, cette 
mcme richcsse littcraire n'a pu expliquer pourquoi line grctfe 
d'organc allogeniquc reussit. Par manque d'explication precise, 
mantes rece"eurs de gretIc d'organe ont etc condamnes ;\ une 
immunosuppression il vic ct ce manque d'information a empcche 
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des changements radicaux dans la tactique therapeutique. Apres 
la decouverte en 1992 que les survivants a long terme avaient un 
microchimerisme persistant. il a ete possible de comprendre ee 
qu'il y avait en commun du point de vue mecanique entre la 
transplantation d'organe et celle de la moelle osseuse. Des lors, 
un principe commun d'immunologie a pu etre efabon~ pour guider 
[,induction de fac;on systematique d'une tolerance aux tissus 
humains. et peut-etrc eventuellement, meme aux xenogretfes. 
Resumen 
Con el desarrollo de la cirugfa de trasplantes, se descubrieron una 
serie de agentes inmunosupresores cada vez mas potentes, 
mejorandose adem as los metodos de preservacion de organos y 
tejidos; tambien se refinaron las tecnicas de histocompatibilidad 
cruzada. Al mismo tiempo. se produjeron numerosas 
innovaciones por 10 que a la tecnica quinirgica se refiere. Todos 
estos esfuerzos han permitido que en el momento actual sea 
posible trasplantar en t!l hombre. con exita. cualquier organo asi 
como las cclulas de la mcdula ost!a. Sin embargo, cl desarrollo de 
los trasplantes dependio b,isicamente de dos investigaciones 
fundamentales: la primera fue el descubrimiento, en 1953, por 
Billingham, Brent y Medawar, de la posible induccion de un 
quimerismo deliberado. propiciado por la tolerancia neonatal. EI 
desarrollo de este descubrimiento permiti6, 15 alios mas tarde 
(1968), realizar con exito el primer trasplante de medula osea. EI 
segundo hito en la historia de los trasplantes fue la demostraci6n, 
a principios de los alios 60. que tanto en cl perro como en cl 
hombre, los injertos alogcnicos pucden Ilcgar a tolerarse por si 
mismos merced a la ayuda de la inmunosuprcsi6n. Sin embargo, a 
finales de 1962 se pens6 erroneamcntc que estos hitos se debian 
a diferentes mecanismos inmunologicos. Este error no se corrigi6 
hasta bien entrada la dccada de los 90. En esta revision hist6rica. 
se resume la ingente litenitura publicada al respecto durante los 
30 ultimos anos. Los progresos realizados en clinica. 
admirablemente documentados, explican cumplidamentc 10 que 
no cansigue la bibliografia re"isada: la aeeptacitin de aloinjertos 
en receptores predestinados a sufrir de por vida un tratamiento 
inmunosupresor. hecho que originani cambios fundamentalcs en 
las pautas terapcuticas. AI descubrirse en 19l)2, que en reccptores 
de un organa trasplantado. con larga sllpervivencia, aparece un 
microquimerismo persistente, fue posible clariticar los 
mecanismos comunes en los trasplantes de ()rganos y de m':dula 
osea. As!. un clariticador principio fundamental de illmunologia 
pudo sintctizarse, por el que se rigen los esfuerzos para indu:ir 
una tolerancia sistem:itiea de los te.lidos hutllanos y tal vez. en 
liitimo termino. de los xenoinjertos. 
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